NCT03225547View on ClinicalTrials.gov

Study of Pembrolizumab and Mifepristone in Patients With Advanced HER2-negative Breast Cancer

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

74

Participants

Timeline

Start Date

February 12, 2018

Primary Completion Date

September 30, 2025

Study Completion Date

September 30, 2025

Conditions
Triple Negative Breast NeoplasmsBreast Cancer
Interventions
DRUG

Pembrolizumab

Pembrolizumab 200mg will be administered to all patients on day 1 of every 21 day cycle.

DRUG

Mifepristone

Mifepristone 300mg will be administered to all patients daily starting the week prior to pembrolizumab.

Trial Locations (1)

60637

University of Chicago, Chicago

All Listed Sponsors
lead

University of Chicago

OTHER